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1. Introduction  
Down syndrome (DS) is associated with many neurological complications including 
cognitive deficits, early-onset dementia -which resembles Alzheimer’s disease- and seizures. 
Although seizures and epilepsy were not mentioned in the original description of DS 
(Down, 1866)  the prevalence of seizures in individuals with DS is now known to be higher 
than in the general population, but lower than in patients with some other types of mental 
retardation (Corvett et al., 1975). Reported rates of epilepsy in DS range from 1 to 13% (see 
table 1) (Tatsumo et al., 1984). Individual series are difficult to compare because of 
differences in inclusion criteria and study populations. The increased seizure susceptibility 
in DS has been attributed to inherent structural and molecular anomalies of the brain or to 
associated medical complications, such as cardiovascular abnormalities and recurrent 
infections. 
Medical interventions in DS have resulted in increased longevity, with estimated life 
expectancy of people with DS in developed countries increasing from an average of 12 years 
in the 1940s to an average of 57,8  years for women and 61,1  years for men (Bittles et al., 
2007). Epilepsy onset in people with DS is age-specific; therefore, because certain 
complications will arise in childhood and others in adulthood, their occurrence is relevant to 
paediatric and adult neurologists. This chapter will provide a critical overview of epilepsy 
in DS.  
                   
Authors  No. of patients Percentage (%) 
Romano et al.    113 13.00
Pueschel et al.   405 8.10
Stafstrom et al.    737 6.40
Table 1. Reported incidence of seizures in patients with Down syndrome in the 1990s 
2. Epidemiology 
Patients with DS show a higher incidence of febrile and non febrile seizures than non-DS 
individuals. Seizures occur in a bimodal distribution in DS, with 40% of individuals first 
developing seizures before 1 year of age and another 40% having an onset in their thirties or 
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later (Pueschel et al., 1991). Boys tend to have an earlier age onset, regardless of seizure type, 
although this may reflect the general male predominance in the infantile spasm group aged 
less than 1 year at onset. The prevalence of epilepsy increases with age and reaches 46% in 
those over 50. In general, about 8% of patients with DS have seizure disorders: 47% of  
them develop partial seizures, 32% infantile spasms and 21% generalized tonic-clonic 
seizures.  
3. Pathophysiology  
The mechanisms underlying the increased seizure susceptibility in DS have not yet been 
completely elucidated. Seizures in infancy have been linked to inherent structural brain 
abnormalities, such as fewer inhibitory neurons, abnormal cortical lamination, persistent 
fetal dendritic morphology, and underdeveloped synaptic profiles (Kemper et al., 1988). 
Concentrations of carbonic anhydrase II, which potentially increases seizure susceptibility, 
are upregulated in the brains of young children with DS and in a mouse model of the 
disorder. (Palminello et al., 2008)  (Tatsuno et al., 1984). 
Altered membrane potassium permeability, which may lead to a decreased voltage 
threshold for spike generation, smaller hyperpolarization following spikes, or increased 
action potential duration, has also been documented in patients with DS. Indeed, in the 
mouse model of trisomy 16, the experimental model of DS, a rapid spike rise and fall was 
recorded from the dorsal root ganglia neurons (Scott et al., 1981) 
In DS there is an overexpression of the 21st chromosome. Many enzymes that are encoded on 
the extra 21st chromosome are known to be actively transcribed, which results in 
overexpression of the enzymes, overconsumption of enzymatic substrates and overproduction 
of metabolic end-products. For example, the superoxide dismutase-1 gene on the 21st 
chromosome is approximately 50% overexpressed, which decreases levels of superoxide (the 
enzyme’s substrate) and increases  levels of hydrogen peroxide (the enzyme’s metabolite, end 
product or output). These primary consequences of genetic overexpression may then produce 
secondary metabolic adaptations as homeostatic systems attempt to compensate. Thus, 
decreased levels of superoxide might alter levels of nitric oxide, peroxynitrate, and nitric oxide 
synthetase, or they may impair aromatic hydroxylation  enzymes and thereby impair 
neurotransmitter synthesis. For another example, increased levels of hydrogen peroxide might 
induce glutathione peroxidase production and thereby increase selenium requirements. Such 
genetically driven enzymatic and metabolic disturbances may help explain why individuals 
with DS appear to be more likely to develop various forms of epilepsy and intractable epilepsy 
(Smigielska-Kuzia et al. 2009). 
Seizures can also be regarded as complications of congenital cardiovascular anomalies in 
children with DS (Marsh et al., 2009). Moyamoya’s disease is a rare vascular complication 
which seems to occur with a higher frequency in children with DS than in those without it. 
Moyamoya’s disease is characterised by a chronic occlusive cerebrovascular alteration of 
unknown pathogenesis in which there is progressive stenosis of the supraclinoid portions of 
the internal carotid arteries. Associated with this stenosis is the formation of convoluted 
arterial collaterals at the base of the brain. Although the presentation of Moyamoya’s disease 
in adults is haemorrhagic, the presenting symptoms in children are typically ischaemic, with 
a fixed unilateral neurological deficit or alternating hemiplegia. Some children with Down’s 
syndrome who have Moyamoya’s disease also develop seizures or involuntary movements. 
(Nascimento et al. 2006). 
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Adult-onset seizures in the absence of dementia are rare in people with DS but might 
become more frequent in the future because of the extension of the lifespan of people with 
the disorder. Late-onset seizures in people with DS seem to be associated with a propensity 
to dementia resembling Alzheimer’s disease. The cause of seizures in adults with DS who 
do not have dementia is not yet clear (Puri, 2001) 
Once seizures occur in the course of dementia in patients with DS, functional decline is often 
rapid, to the point where floor effects preclude further cognitive testing. Seizures are 
common in people with early-onset Alzheimer’s disease associated with genetic defects, 
including mutations that result in overexpression of amyloid-ǃ, such as those involving 
presenilin 1 genes. Animals with overexpression of the APP gene have a lower threshold to 
induced seizures. High concentrations of amyloid-ǃ caused by APP overexpression result in 
epileptiform activity in vivo, even in the absence of neurodegeneration, suggesting that 
these high concentrations are a direct cause of epilepsy. (T Llot 2010).  
4. Clinical and electrophysiological features  
Epilepsy in DS showed a bimodal distribution; in the younger age group, infantile spasms 
and tonic-clonic seizures with myoclonus are the main finding, whereas older patients often 
have partial simplex or partial complex seizures as well as tonic-clonic seizures (Pueschel et 
al., 1991).  
4.1 Seizures in infancy and childhood 
It is currently known that there is a higher incidence of seizures, particularly infantile 
spasms, in DS compared to the general population. Few children with DS have their first 
epileptic attacks after the age of 3. These patients often have partial simplex or partial 
complex seizures as well as tonic-clonic seizures.  
Infantile spasms are an age-dependent epilepsy that most frequently appears in the first 
year of life, with ictal episodes consisting of spasms that usually occur in clusters  
(Dulac et al., 1994). There is a characteristic chaotic and high-voltage interictal 
electroencephalography (EEG) pattern, which, when typical, is called hypsarrhythmia. 
West’s syndrome is the term employed when such spasms are concomitant with delayed 
psychomotor development and EEG hypsarrhythmia. It has been reported that 6.4% of 737 
patients with DS had epilepsy, and 12.8% of epileptic patients with DS had West syndrome. 
In addition, it has been reported that 8.1% of 405 patients with DS had epilepsy in 
childhood, and 18% of the epileptic patients were diagnosed as having infantile spasms. 
Infantile spasms, which often indicate poor prognosis in the general population, do not 
seem to be associated with difficulties in long-term seizure control in children with DS. 
However, in children with DS who have infantile spasms, there seems to be a substantial 
association between treatment and developmental quotient as well as progression to 
autistic features. There are no long-term studies of the intellectual outcome of children 
with DS in whom infantile spasms were successfully controlled. In our experience, 
patients with Down syndrome with infantile spasms and abnormal but non-
hypsarrhythmic EEG may have poor disease progression (figure 1 a and b & Figure 2 a 
and b), with persistence of seizures and severely impaired psychomotor development  
(Nascimento & Ortez 2009).  
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a) 
 
 
b) 
 
Fig. 1. EEG of an 8m21d boy with DS.  a)  In a sleep stage, no physiological graphoelements 
were observed and there were very frequent multifocal paroxysms in the form of high-
voltage spike-wave complexes; paroxistic alterations persisted during the waking stage. b) 
There was an electroclinical episode consisting of the emergence of a high-voltage spike-
wave complex clinically accompanied by extension and abduction of the upper limbs and a 
slight extension of the lower limbs. Note the contraction recorded over both deltoid muscles. 
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a) 
 
 
b) 
 
 
Fig. 2. EEG of a 3-year-old girl with DS initially affected by West’s syndrome who then 
evolved to Lennox-Gastaut syndrome. a) Tonic seizure: Ictal electroencephalography (EEG) 
shows a diphasic, mid-voltage slow wave, followed by recruiting low-voltage fast activity, 
replaced by spike and polyspike and wave discharges; tonic contraction was recorded over 
both deltoid muscles. b) Waking stage: brain activity constituted by an association of delta 
and theta waves and low-voltage beta rhythms, with a diffuse distribution. Frequent focal 
paroxysms were observed in the form of spikes and complex spike-waves of irregular 
medium and high amplitude, located independently in the frontal and parieto-occipital 
regions of both hemispheres. 
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There is a chance that DS in association with West’s syndrome may evolve to Lennox-Gastaut 
syndrome (LGS). LGS has classically been defined by the triad of drug-resistant epilepsy with 
multiple seizure types, typically diurnal atonic as well as atypical absences, and mainly 
nocturnal tonic seizures; electroencephalography abnormalities, principally diffuse slow spike-
wave or polyspike-wave discharges during wakefulness and bursts of diffuse fast rhythms at 
10–20 Hz during sleep; mental deterioration of variable severity as well as behavioural 
disturbances may also occur (Gastaut et al., 1966; Dulac & N’Guyen, 1993). A series of DS 
patients with late onset LGS has been described, having a higher frequency of reflex seizures 
and more cognitive impairment ( Figure 3). (Ferlazzo et al., 2009) 
 
 
Fig. 3. 7-year-old boy. Tonic seizure triggered by a sudden noise (black arrow). Note the 
marked tonic contraction recorded over both deltoid muscles. Ictal electroencephalography 
(EEG) shows a diphasic, mid-voltage slow wave, followed by recruiting low-voltage fast 
activity, replaced by spike and polyspike and wave discharges, predominant over anterior 
leads, lasting for about 10 s. Electrocardiography shows an increased heart rate during 
seizure. Zoom: detail of the ictal discharge recorded over the vertex derivation, where 
muscular artifacts are less evident. (Ferlazzo et al. 2009) 
Why do some infants with DS develop infantile spasms, whereas others with the same 
disorder do not? The cause has never been fully understood. Naming DS as the ‘‘cause’’ of 
the infantile spasms may, therefore, be at best inaccurate and at worst totally misleading, 
suggesting that we understand why the disorder has arisen in that particular child when DS 
has merely predisposed the child to infantile spasms. Only a few infants with Down 
syndrome develop infantile spasms, yet Down syndrome is accepted (Eisermann et al., 2003) 
as a ‘‘cause,’’ and frequently such infants are not given a brain scan. As a result, other 
authors have proposed adopting a terminology that distinguishes the underlying etiology 
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from the cause. According to this scheme, we use the term proven etiology to refer to any 
identified underlying neurological disorder, and employ cause as a more specific term that 
may be a complex and less well-understood sequence or combination of events. Perhaps 
because of the many different diagnoses that can be made in these infants and the 
developmental outcomes associated with them, classification into diagnostic groups has 
been commonly attempted. (Osborne et al., 2010) 
The most frequent nomenclature has classified cases as either symptomatic, cryptogenic, or 
idiopathic, but unfortunately there is no clear definition of these terms (Lux & Osborne, 
2005). “Symptomatic” is often used to indicate that a prior disorder exists. “Cryptogenic” is 
often used to mean that there must be an etiology, but that one has not been found. A recent 
report of the International League Against Epilepsy (ILAE) Commission on Classification 
and Terminology also suggests that the terms idiopathic, symptomatic, and cryptogenic 
should be replaced (Berg et al., 2010). It has suggested broad etiologic categories: genetic, 
structural–metabolic, and unknown. 
4.2 Seizure in adulthood 
The prevalence of epilepsy in DS has increased with longevity, reaching 46% in those older 
than 50. Descriptions of late-onset epilepsy in the absence of dementia in DS patients 
(LOMEDS) are rare, but since life expectancy of DS patients has markedly increased, 
LOMEDS may be more frequent than currently acknowledged and should be considered in 
the differential diagnosis of adult-onset myoclonic epilepsies. The electroclinical features are 
myoclonic jerks on awakening and generalised tonic-clonic seizures, with generalised spike 
and wave on EEG, and progressive dementia (Moller et al., 2002). 
Familial Alzheimer’s dementia (FAD) and progressive myoclonic epilepsy (Unverricht–
Lundborg type) are both linked to chromosome 21. In an interesting study of 68 DS adults, it 
was found that among those with a history of seizures, individuals aged over 45 years were 
significantly more likely to develop AD than those under 45, and up to 84% of demented 
individuals with DS developed seizures. It suggests that late-onset epilepsy in DS is 
associated with AD, while early-onset epilepsy is associated with an absence of dementia 
(Menéndez, 2005). 
Seizures in adults with DS differ from those in adults with Alzheimer’s disease who do not 
have DS: myoclonic seizures usually occur late in the course of Alzheimer’s disease whereas 
partial or tonic–clonic seizures occur in adults with Down’s syndrome and are often 
precursors to cognitive decline. Adults with DS aged over 45 years who have seizures are 
substantially more likely to develop signs of Alzheimer’s disease (Puri et al; 2001). Once 
seizures occur in the course of dementia in patients with DS, functional decline is often 
rapid, to the point where floor effects preclude further cognitive testing. Seizures are 
common in people with early-onset Alzheimer’s disease associated with genetic defects, 
including mutations that result in overexpression of amyloid-ǃ, such as those involving 
presenilin 1 genes.  
Animals with overexpression of the APP gene have a lower threshold to induced seizures. 
High concentrations of amyloid-ǃ caused by APP overexpression result in epileptiform 
activity in vivo, even in the absence of neurodegeneration, suggesting these high 
concentrations directly as a cause of aberrant neuronal network synchronisation. Slowing 
of the dominant occipital rhythm seems to be associated with dementia in individuals 
with DS, and the frequency of dominant occipital activity decreases as cognition 
deteriorates. 
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4.3 Seizure in Alzheimer´s and DS  
Despite the apparent clinical heterogeneity in aged individuals with DS, age-associated AD-
like neuropathology is a consistent feature. This is due to the fact that trisomy 21 leads to a 
dose-dependent increase in the production of the APP and subsequently the production of 
the amyloidogenic fragments leading to early and predominant senile plaque formation. 
Ten percent of patients with AD have seizures, and another 10% have myoclonus. The 
incidence of seizures is about 10 times higher than expected in a reference population. Both 
seizures and myoclonus, individually or together, are manifestations of AD and may be seen 
at any time in the course of the illness, but myoclonus is often a late manifestation. (Volicer 
et al., 1995) 
4.4 Electroencephalography (EEG) features  
Individuals with DS have increased absolute power in all the EEG bands, independent of 
cognition functions. In the power spectrum of the resting EEG, there is a cognition-related 
increase in power at theta- and alpha-slowing. Furthermore, in the stimulated EEG, there 
are several cognition-related abnormalities, such as decreased responses to 12-Hz 
stimulation and decreased integral of beta- and gamma-band responses, indicative of 
decreased responsiveness to photic stimulation. Other reports note an increase in power at 
theta and delta in children with DS during sleep. (S’migielska-Kuzia et al., 2009). There is a 
significant increase in theta, delta, and beta power and a decrease in alpha compared with 
non-DS with epilepsy. (Figure 3) 
 
 
Fig. 3. Spectral power of alpha, theta, delta, and beta bands of DS, n = 12, DS Non-Epilepsy 
(Non-Epi) n=10 versus Non-DS (epileptic children) n = 28. Alpha Non-DS versus alpha DS P 
< .001; alpha Non-DS versus alpha DS Non-Epi P = .001; alpha DS versus alpha DS Non-Epi 
P < .001; theta Non-DS versus theta DS P = .767; theta Non-DS versus theta DS Non-Epi P < 
.001; theta DS versus theta DS Non-Epi P < .001; delta Non-DS versus delta DS P < .001; 
delta Non-DS versus delta DS Non-Epi P < .001; delta DS versus delta DS Non-Epi P < 
.001;beta Non-DS versus beta DS P < .001; beta Non-DS versus beta DS Non-Epi P < .001; 
beta DS versus beta DS Non-Epi P < .001. (S’migielska-Kuzia et al., 2009) 
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5. Treatment of epilepsy in DS 
The pharmacological treatment of epilepsy in DS is no different from that of other patients 
diagnosed with epilepsy; the key is proper clinical and electrical classification to guide 
epilepsy treatment and thereby obtain good therapeutic results. 
Although the cognitive profiles of newer antiepileptic drugs (AEDs) are in general better 
than those of older antiepileptic drugs, neurological adverse events do occur, including 
somnolence, distractibility, dizziness, and an altered pattern of sleep architecture. 
Individuals with DS have an unusually high number of side-effects from phenytoin 
(Tsiouris et al., 2002).  
Over time, with the advent of advances in molecular biology, many AEDs have been 
uncovered, so they have come to be classified as first-, second- and third-generation drugs. 
(see table 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Antipileptica drugs by generation 
Figures 4 a & b and table 3 describe the different mechanisms of action demonstrated for  
antiepileptic drugs (AEDs).  
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Fig. 4. a& b Proposed mechanisms of action of currently available AEDs at excitatory and 
inhibitory synapses. 
a | Currently available antiepileptic drugs (AEDs) are thought to target several molecules at 
the excitatory synapse. These include voltage-gated Na+ channels, synaptic vesicle 
glycoprotein 2A (SV2A), the ǂ2δ subunit of the voltage-gated Ca2+ channel, AMPA (ǂ-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors, and NMDA (N-methyl-D-
aspartate) receptors. Many of the AEDs can modulate voltage-gated Na+ channels. This 
would be expected to decrease depolarization-induced Ca+ influx and vesicular release of 
neurotransmitters. In addition, lacosamide is thought to enhance slow inactivation of 
voltage-gated Na+ channels. This effect is different from that of other listed AEDs, which are 
thought to enhance fast inactivation. Levetiracetam is the only available drug that binds to 
SV2A, which might have a role in neurotransmitter release. Gabapentin and pregabalin  
bind to the a2δ subunit of voltage-gated Ca2+ channels, which is thought to be associated 
with a decrease in neurotransmitter release. Excitatory neurotransmission at the 
postsynaptic membrane can be limited by topiramate (acting on AMPA and kainate 
receptors) and felbamate (acting on NMDA receptors). 
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 b | AED targets at inhibitory synapses have also been proposed. These include the g-
aminobutyric acid (GABA) transporter GAT1 (also known as SLC6A1), which is inhibited by 
tiagabine, leading to a decrease in GABA uptake into presynaptic terminals and 
surrounding glia; and GABA transaminase (GABA-T), which is irreversibly inhibited by 
vigabatrin. This decreases the metabolism of GABA in presynaptic terminals and glial cells. 
The benzodiazepines, barbiturates, topiramate and felbamate have been found to enhance 
inhibitory neurotransmission by allosterically modulating GABAA receptor-mediated Cl− 
currents. However, the action of each of these drugs is different and is dependent on the 
subunit conformation of the GABAA receptor complex. GAD, glutamic acid decarboxylase. 
(Bailer & White 2010). 
 
 Blockade of 
voltage-
dependent 
sodium 
channels 
Increase in 
brain or 
synaptic 
GABA 
levels 
Selective 
potentiation 
of GABAA-
mediated 
responses 
Direct 
facilitation 
or chloride-
ion influx 
Blockade 
of 
calcium 
channels
Other 
actions 
First generation 
AEDs. 
 
Benzodiazepines - - ++ - - - 
Carbamazepine ++ ? - - + + 
Ethosuximide - - - - ++ - 
Phenobarbital - + + ++ ? + 
Phenytoin ++ - - - ? + 
Valproic acid ? + ? - + ++ 
Second 
generation AEDs.
 
Felbamate ++ + + - + + 
Gabapentin ? ? - - ++ ? 
Lamotrigine ++ + - - ++ + 
Levetiracetam - ? + - + ++ 
Oxcarbamacepine ++ ? - - + + 
Pregabalin - - - - ++ - 
Tiagabaline - ++ - - - - 
Topiramate ++ + + - + + 
Vigabatrin - ++ - - - - 
Zonisamide ++ ? - - ++ + 
++ primary action; + secundari action; -, no action described; ?, controversial evidence.  
Table 3. Main Mechanism of action of AEDs.  
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Table 4 describes the different AEDs and the main indication for the type of epilepsy 
diagnosed. Table 5 describes the AEDs, dose in children and adults and side effects. 
 
FIRST GENERATION 
AEDs 
MAIN INDICATION 
Benzodiazepines Status epilpeticus. Partial an generalizated seizures 
Carbamazepine Partial seizures (with and whithout secondary 
generalization) and primarily generalized tonic-clonic 
seizures. 
Ethosuximide Absence seizures, continuous spike – waves during slow 
sleep. 
Phenytoin Partial seizures (with and whithout secondary 
generalization) and primarily generalized tonic-clonic 
seizures. Status epilepticus.  
Valproic acid Generalized and partial seizures. Status epilepticus.  
SECOND GENERATION 
AEDs 
MAIN INDICATION 
Felbamate Severe epilepsies, particulary Lennox-Gastaut syndrome, 
refractory to all other AEDs. 
Gabapentin Partial seizures (with and whithout secondary 
generalization) 
Lamotrigine Partial and generalized seizures (may aggravate severe 
myoclonic epilepsy of infancy) 
Levetiracetam Partial and probably generalized seizures. 
Oxcarbamacepine Partial seizures (with and whithout secondary 
generalization) and primarily generalized tonic-clonic 
seizures. 
Pregabalin Partial seizures (with and whithout secondary 
generalization). 
Tiagabaline Partial seizures (with and whithout secondary 
generalization). 
Topiramate Partial and generalized seizures (efficacy against absence 
seizures not proven) 
Vigabatrin Infantile spasms and West Sindrome. Partial seizure (with 
and whithout secondary generalization) refractory to all 
other AEDs. 
Zonisamide Partial and, probably, generalized seizures. 
 
Table 4. AEDs and the main indication for the type of epilepsy diagnosed 
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AEDs 
 
Childrens 
Dose 
mg/kg/d 
 
Adults 
Dose mg/day. 
Side Effects. 
Carbamacepine 15-30  600 – 2000 mg divided into 
up to 4 doses a day. 
Skin rash, if allergic to 
carbamazepine. Diplopia 
(double vision), ataxia 
(unsteadiness) and nausea 
may occur initially or if 
the dose is too high. 
Clobazam 0,1-0,2  20 - 50 mg divided into 1 or 
2 doses a day. 
Drowsiness may occur but 
this drug is less sedating 
than clonazepam or 
diazepam. Tolerance may 
develop. 
Clonazepam 0,5-0,8 1 – 4 mg divided into 2 
doses a day. 
Drowsiness and sedation 
are quite common but 
these may wear off.  
Ethosuximide 20-35 750 – 1500 mg divided  into 
2 or 3 doses a day. 
Nausea and drowsiness 
may occur initially or if 
the dose is too high. 
Anorexia (weight loss). 
Gabapentine 30 1800 – 3600 mg  divided 
into 3 doses a day. 
Drowsiness, dizziness, 
and headache 
Levetiracetam 20-60 1000 – 3000 mg divided into 
2 doses a day. 
Dizziness, drowsiness, 
irritability, behavioural 
problems, insomnia, 
ataxia (unsteadiness), 
tremor, headache, nausea 
may occur in high dosages 
or when doses are 
increased, but will usually 
disappear after a few 
days. 
Lamotrigine 5-15  
1-5 + VPA 
 
100  - 200mg if taken alone 
or if also taking sodium 
valproate. 200 – 400 mg if 
also taking phenytoin , 
Skin rash if allergic to 
lamotrigine. Drowsiness, 
diplopia (double vision), 
dizziness, headache, 
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AEDs 
 
Childrens 
Dose 
mg/kg/d 
 
Adults 
Dose mg/day. 
Side Effects. 
phenobarbitone or 
carbamazepine. 
insomnia, tremor and flu-
like  symptoms. 
Oxcarbamazepine 15-30 1200 - 2400mg divided into 
2 or 3 doses a day. 
Skin rash, if allergic to 
oxcarbazepine. Diplopia 
(double vision), ataxia 
(unsteadiness), headache, 
nausea, confusion and 
vomiting. 
Phenobarbital 3-5 30 – 180 mg divided into 2 
doses a day. 
Drowsiness may occur 
initially. Lethargy, 
sedation and slowing of 
mental performance may 
be long-lasting. 
Phenytoin 5-10 150 – 600 mg divided into 1 
or 2 doses a day. 
Skin rash if allergic to 
phenytoin. Drowsiness, 
ataxia (unsteadiness) and 
slurred speech may occur 
if the dose is too high. 
Coarsening of facial 
features, overgrowth of 
gums, excess hair growth 
and acne may occur with 
prolonged therapy (over 
many years), as can some 
anaemias. 
Topiramate 5-9 Up to 400 mg daily if taken 
alone. Usually 200 – 400 mg 
daily if taken with other 
anti-epileptic drugs, up to 
800 mg. 
Headache, drowsiness, 
dizziness, paraesthesia 
(pins and needles in hands 
and feet), loss of weight, 
and kidney stones. Speech 
disorder, impaired 
memory and 
concentration may occur 
when dose is increased 
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AEDs 
 
Childrens 
Dose 
mg/kg/d 
 
Adults 
Dose mg/day. 
Side Effects. 
but will usually disappear 
after a few days.  
Sodium 
valproate 
20-50 400 – 2000 mg divided into 
1 or 2 doses a day. 
Drowsiness and tremor 
are infrequent side effects. 
Hair loss occurs in some 
people but is not usually 
severe and is usually 
reversible if the dose is 
reduced. Weight gain may 
occur. Liver. damage is 
rare. Sodium valproate 
has been associated with 
increased incidence of 
Polycystic  Ovary 
Syndrome and menstrual 
irregularitiesthan other 
AEDs, if taken in 
pregnancy. 
Vigabatrine 50-200 1000 – 4000 mg divided into 
1 or 2 doses a day. 
Drowsiness, behaviour 
and mood changes. 
Psychotic reactions have 
been reported. Visual field 
defects have been 
reported in one in three 
people taking vigabatrin 
in the long term.  
Zonizamide 4-8 300  - 500mg divided into 1 
or 2 doses a day. 
Skin rash if allergic to 
zonisamide. Drowsiness, 
dizziness, weight  
loss, kidney stones, 
confusion, cognitive 
slowing, agitation, 
irritability, 
depression, 
Table 5. AEDs, dose in children and adults. Side effects.  
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6. Conclusions 
The findings of the last decade regarding the significant percentage of children with DS and 
epilepsy (approximately 1 in 10) highlight the importance of the awareness that physicians 
should start developing about this association so that they can intervene as early as possible 
when seizures are suspected, to maximize the patient’s development and improve quality of 
life as much as possible. 
The diagnosis, classification and treatment of epilepsy in DS must follow the guidelines 
applied to the general population. 
Children with DS have a greater predisposition to epilepsy (specifically to West Syndrome 
and infantile spasms) attributed to structural and molecular abnormalities. In contrast, in 
adults with DS, epilepsy is associated with the accumulation of amyloid-ǃ, due to the 
expression of APP that is observed in DS patients with early-onset Alzheimer-like dementia. 
The prognosis of patients with DS and epilepsy will depend on several factors:  type of 
epilepsy, age of initiation, etiology, early diagnosis and treatment’s response. Epilepsy in 
patients with DS, as well as in the general population, in most cases represents an alteration 
of brain function that can be detrimental to neurological development; this produces a great 
amount of anxiety and concern in their parents and relatives. For this reason, all of the 
prognostic factors must be carefully taken into account when considering each individual 
case. The disease, its control and its management should be discussed in a clear and simple 
way with the family.  
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